Your browser doesn't support javascript.
loading
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Paquette, Brice; Vernerey, Dewi; Chauffert, Bruno; Dabakuyo, Sandrine; Feuvret, Loic; Taillandier, Luc; Frappaz, Didier; Taillia, Hervé; Schott, Roland; Ducray, François; Fabbro, Michel; Tennevet, Isabelle; Ghiringhelli, François; Guillamo, Jean-Sébastien; Durando, Xavier; Castera, Daniel; Frenay, Marc; Campello, Chantal; Dalban, Cécile; Skrzypski, Jérome; Chinot, Olivier; Anota, Amélie; Bonnetain, Franck.
Afiliación
  • Paquette B; Methodological and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, EA 3181, France.
  • Vernerey D; Department of Digestive Surgery and Liver Transplantation, University Hospital of Besançon, Besançon, France.
  • Chauffert B; Methodological and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, EA 3181, France.
  • Dabakuyo S; Department of Medical Oncology, University Hospital, EA 4666, Amiens, France.
  • Feuvret L; Biostatistics and Quality of life Unit, Centre Georges François Leclerc, Dijon, France.
  • Taillandier L; Quality of Life in Oncology National Platform, Besançon, France.
  • Frappaz D; Department of Radiotherapy, Pitié-Salpetrière University Hospital, Paris, France.
  • Taillia H; Department of Neurology, University Hospital, Nancy, France.
  • Schott R; Department of Oncology, Leon Berard Centre for Fight against Cancer, Lyon, France.
  • Ducray F; Department of Neurology, HIA Val de Grace, Paris, France.
  • Fabbro M; Department of Oncology, Paul Strauss Centre for Fight against Cancer, Strasbourg, France.
  • Tennevet I; Department of Neurology, University Hospital, Lyon, France.
  • Ghiringhelli F; Department of Oncology, Val d'Aurelle Center for Fight against Cancer, Montpellier, France.
  • Guillamo JS; Department of Oncology, Henri Becquerel Center for Fight against Cancer, Rouen, France.
  • Durando X; Department of Oncology, GF Leclerc Center for Fight against Cancer, Dijon, France.
  • Castera D; Department of Neurology, University Hospital, Caen, France.
  • Frenay M; Department of Oncology, Jean Perrin Center for Fight against Cancer, Clermont-Ferrand, France.
  • Campello C; Clinique Saint Pierre, Perpignan, France.
  • Dalban C; Department of Oncology, Antoine Lacassagne Center for Fight against Cancer, Nice, France.
  • Skrzypski J; Department of Neurology, University Hospital, Nimes, France.
  • Chinot O; Biostatistics and Quality of life Unit, Centre Georges François Leclerc, Dijon, France.
  • Anota A; Methodology Unit, GF Leclerc Center for Fight against Cancer, Dijon, France.
  • Bonnetain F; Department of Neuro-Oncology, University Hospital La Timone, Marseille, France.
Cancer Med ; 5(8): 1753-64, 2016 08.
Article en En | MEDLINE | ID: mdl-27252150
Glioblastoma is the most common malignant brain tumor in adults. Baseline health-related quality of life (HRQoL) is a major subject of concern for these patients. We aimed to assess the independent prognostic value of HRQoL in unresectable glioblastoma (UGB) patients for death risk stratification. One hundred and thirty-four patients with UGB were enrolled from the TEMAVIR trial. HRQoL was evaluated at baseline using the EORTC QLQ-C30 and BN20 brain cancer module. Clinical and HRQoL parameters were evaluated in univariable and multivariable Cox analysis as prognostic factors for overall survival (OS). Performance assessment and internal validation of the final model were evaluated with Harrel's C-index, calibration plot, and bootstrap sample procedure. Two OS independent predictors were identified: future uncertainty and sensitivity deficit. The final model exhibited good calibration and acceptable discrimination (C statistic = 0.63). The internal validity of the model was verified with robust uncertainties around the hazard ratio. The prognostic score identified three groups of patients with distinctly different risk profiles with median OS estimated at 16.2, 9.2, and 4.5 months. We demonstrated the additional prognostic value of HRQoL in UGB for death risk stratification and provided a score that may help to guide clinical management and stratification in future clinical trials.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Año: 2016 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Año: 2016 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos